A massive database study performed recently in France demonstrates that genetic testing of non-small cell lung cancer (NSCLC) tumors for disease-relevant biomarkers is feasible, and indeed already helps guide treatment strategies for patients. France’s National Cancer Institute funds routine assessment of genetic alterations in six genes for NSCLC patients: EGFR, KRAS, ALK, BRAF, HER2, and PI3K. Since April 2012, these genetic analyses have been collected into a database. By now, biomarker assessments have been performed for 10,000 NSCLC patients. Of the patients for whom treatment data was available, over half received therapies guided directly by their biomarker testing profile. For example, over half of patients who were found to have a mutation in the EGFR gene were treated with EGFR inhibitors. As the database continues to grow, researchers recommend that newer biomarkers, like the ROS1 gene, should be added to the analysis. Furthermore, they urge that the availability of clinical trials of biomarker-targeted treatments needs to be increased.